BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17034469)

  • 1. Muir-Torre syndrome: Diagnostic and screening guidelines.
    Jones B; Oh C; Mangold E; Egan CA
    Australas J Dermatol; 2006 Nov; 47(4):266-9. PubMed ID: 17034469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An illustrative case of Muir-Torre syndrome: contribution of immunohistochemical analysis in identifying indicator sebaceous lesions.
    Marazza G; Masouyé I; Taylor S; Prins C; Gaudin T; Saurat JH; French LE
    Arch Dermatol; 2006 Aug; 142(8):1039-42. PubMed ID: 16924054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
    Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
    Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Muir-Torre syndrome and familial colorectal cancer: 2 families with molecular genetic analysis].
    Doré MX; Dieumegard B; Grandjouan S; Avril MF; Martinet C; Ducreux M; Lasser P; Bressac-de Paillerets B
    Ann Dermatol Venereol; 1999; 126(8-9):582-6. PubMed ID: 10530344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The frequency of Muir-Torre syndrome among Lynch syndrome families.
    South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
    J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous Sebaceous Lesions in a Patient With MUTYH-Associated Polyposis Mimicking Muir-Torre Syndrome.
    Kacerovska D; Drlik L; Slezakova L; Michal M; Stehlik J; Sedivcova M; Hadravsky L; Kazakov DV
    Am J Dermatopathol; 2016 Dec; 38(12):915-923. PubMed ID: 27870730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.
    Perera S; Ramyar L; Mitri A; Pollett A; Gallinger S; Speevak MD; Aronson M; Bapat B
    J Hum Genet; 2010 Jan; 55(1):37-41. PubMed ID: 19911012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muir-Torre syndrome: clinical features and molecular genetic analysis.
    Esche C; Kruse R; Lamberti C; Friedl W; Propping P; Lehmann P; Ruzicka T
    Br J Dermatol; 1997 Jun; 136(6):913-7. PubMed ID: 9217825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics.
    Orta L; Klimstra DS; Qin J; Mecca P; Tang LH; Busam KJ; Shia J
    Am J Surg Pathol; 2009 Jun; 33(6):934-44. PubMed ID: 19342947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Muir-Torre syndrome: a case report and review of the literature.
    Pettey AA; Walsh JS
    Cutis; 2005 Mar; 75(3):149-55. PubMed ID: 15839358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mutation in the MSH2 gene in Muir-Torre syndrome].
    Godard V; Coulet F; Bernaudin JF; Housset M; Soubrier F
    Ann Dermatol Venereol; 1999; 126(8-9):600-3. PubMed ID: 10530347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical follow-up and presence of visceral tumors in 12 patients with sebaceous gland tumors].
    Mercader P; García-Melgares ML; Roche E; Sánchez-Carazo JL; Alegre-de Miquel V
    Actas Dermosifiliogr; 2008 Sep; 99(7):532-9. PubMed ID: 18682166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination.
    Yanaba K; Nakagawa H; Takeda Y; Koyama N; Sugano K
    Br J Dermatol; 2008 Jan; 158(1):150-6. PubMed ID: 17941949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. All patients with sebaceous gland neoplasms should be screened for Muir-Torre syndrome.
    Ingram JR; Griffiths AP; Roberts DL
    Clin Exp Dermatol; 2009 Mar; 34(2):264-6. PubMed ID: 19187311
    [No Abstract]   [Full Text] [Related]  

  • 15. [Multiple sebaceous tumors with colon cancer--Muir-Torre syndrome].
    Vajda A; Scharrer K; Baló-Banga JM
    Orv Hetil; 2003 May; 144(20):985-9. PubMed ID: 12830729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias.
    Kruse R; Rütten A; Schweiger N; Jakob E; Mathiak M; Propping P; Mangold E; Bisceglia M; Ruzicka T
    J Invest Dermatol; 2003 May; 120(5):858-64. PubMed ID: 12713593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability in Muir-Torre syndrome.
    Honchel R; Halling KC; Schaid DJ; Pittelkow M; Thibodeau SN
    Cancer Res; 1994 Mar; 54(5):1159-63. PubMed ID: 8118799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification in daily practice of patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer): revised Bethesda guidelines-based approach versus molecular screening.
    Julié C; Trésallet C; Brouquet A; Vallot C; Zimmermann U; Mitry E; Radvanyi F; Rouleau E; Lidereau R; Coulet F; Olschwang S; Frébourg T; Rougier P; Nordlinger B; Laurent-Puig P; Penna C; Boileau C; Franc B; Muti C; Hofmann-Radvanyi H
    Am J Gastroenterol; 2008 Nov; 103(11):2825-35; quiz 2836. PubMed ID: 18759827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Muir-Torre syndrome and HNPCC: importance of clinical diagnosis and genetic investigation in family members].
    Strul H; Rozen P; Naiman T; Shomrat R
    Harefuah; 1999 Feb; 136(4):274-6, 339. PubMed ID: 10914216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sebaceous neoplasms and the immunoprofile of mismatch-repair proteins as a screening target for syndromic cases.
    Boennelycke M; Thomsen BM; Holck S
    Pathol Res Pract; 2015 Jan; 211(1):78-82. PubMed ID: 25457183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.